Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

NCT07519330 ↗

Phase 2 Recruiting 45 enrolled Huahui Health

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks. All treated patients will also undergo a follow-up period after last study drug treatment.

Timeline

Start: 2026-05-14
Primary completion: 2028-02-28
Completion: 2028-03-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HH-006	Monoclonal antibody	240 mg	Subcutaneous

Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

Summary

Timeline

Drugs

Indications